Guy Martin
ReporterThe Pharma Letter
Guy Martin has been a journalist since 2008.
He writes about all areas of pharma and biotech, and related business news.
He has a special interest in emerging technologies leading to the development of personalized medicines, along with the changes this will bring to the pharmaceutical industry and beyond.
Today's issue
Refine Search
Latest from Guy Martin
Pharmaceutical
Nobody is surprised now when pharma companies that are presenting data at scientific conferences choose to focus on real-world evidence (RWE) as much as, or more than, on their results from randomized control trials. 20 October 2017
Pharmaceutical
A look into whether the issue of nationality matters when pharma companies are selecting their leaders. 6 October 2017
Pharmaceutical
The European Commission (EC) approval of a combination involving Kisqali (ribociclib) for a large breast cancer indication last month led a senior executive from Swiss pharma giant Novartis to proclaim that it proved the company’s ‘recognized leadership in cancer research’. 27 September 2017
Pharmaceutical
News on chimeric antigen receptor T-cell (CAR-T) therapies in the last week has added to the immediacy of a question that has been hanging over these individually-tailored cancer treatments as they have edged closer to market – how on earth are health systems going to afford them? 1 September 2017
Biotechnology
Antony Odell, chief executive of UK-based regenerative medicine company Tissue Regenix, is honest about the industry’s mixed fortunes so far when it comes to turning talk about regenerative medicine into effective products. 25 August 2017
Biosimilars
There is little doubt that, since it started life in the drug development industry just five years ago, Samsung Bioepis has passed its first test with flying colors. 22 August 2017
Biotechnology
A number of questions have been bouncing around the early-stage drug discovery community for a number of years now, particularly in the UK and Europe where a perception abounds that attractive funding opportunities are harder to come by than in the USA. 15 August 2017
Pharmaceutical
Jeevan Virk, commercial director for the UK and Ireland at French molecular nuclear medicine specialist Advanced Accelerator Applications, admitted that it was not a shock when the National Institute for Health and Care Excellence (NICE) published draft guidance not recommending Lutathera (Lutetium Lu 177 dotatate) for treating neuroendocrine tumors of gastrointestinal and pancreatic origin. 11 August 2017
Pharmaceutical
Before 2012, Takeda Pharmaceutical did not have a presence in the global vaccines space. 4 August 2017
Pharmaceutical
However it ends, AstraZeneca, the summer of 2017 will not be remembered as a quiet period in the recent history of the Anglo-Swedish pharma company. 14 July 2017
Pharmaceutical
Anyone unfamiliar with pharma might be puzzled by how often the word ‘innovation’ comes up in dialogue, campaigning and marketing messages. 24 June 2017
Pharmaceutical
Brexit, political instability, economic uncertainty, an aging population increasingly suffering from chronic conditions, a cost-effectiveness watchdog looking to save every penny possible when paying for new medicines and a National Health Service (NHS) reportedly facing its worst crisis in generations – the challenges facing the UK health sector appear almost insurmountable. 21 June 2017
Biotechnology
With so much of the exciting data at ASCO 2017 again surrounding cancer immunotherapies, The Pharma Letter finds confidence that more will follow in the footsteps of Merck & Co's Keytruda (pembrolizumab). 8 June 2017
Biosimilars
With data on so many innovative but expensive new oncology treatments being presented at ASCO 2017, it is a crucial period for biosimilars of three of the world's biggest-selling cancer drugs to deliver their promised savings, and this feature looks at the progress of these copycat biologics in reaching markets and patients. 1 June 2017
Pharmaceutical
Germany’s Merck KGaA has not appeared near the summit of any rankings on top pharma companies by oncology revenue in recent years, with earnings from its sole cancer product Erbitux (cetuximab) dropping to below $1 billion in 2016. 31 May 2017
Biotechnology
While drug developers deserve credit for the enormous progress achieved in hepatology, use of the word ‘cured’ can perhaps be seen as unhelpful given that global statistics paint a very different picture of the impact of viral hepatitis. 22 May 2017
Biotechnology
With a global society of researchers, regulators and clinicians celebrating its 25th anniversary, 2017 is a good time to consider how cellular therapies have progressed in this period, where they are now, and the obstacles preventing their advance in the next quarter-century. 16 May 2017
Pharmaceutical
While pharma companies pile into areas such as oncology and central nervous system disorders in the hope that they can offer the next lifesaving treatment, the fact that there are currently just six global players in the vaccines space indicates that it is an enormously challenging area despite the enormous benefits of immunizations for healthcare systems. 9 May 2017
Biotechnology
France-headquartered Advanced Accelerator Applications is different not just because of its confidence in molecular nuclear medicine, but also because of its theragnostic approach, chief executive Stefano Buono tells The Pharma Letter. 8 May 2017
Biotechnology
In a claim that will make patient groups, PR companies and communication teams at pharma companies sit up and listen, the market access director for Swiss pharma giant Roche has said that pressure from the public and media was key to an innovative cancer drug being made available for Scottish women on the National Health Service (NHS). 27 April 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze